title: Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites.
abstract: Single-dose and multiple-dose pharmacokinetics of terodiline were studied in 20 healthy volunteers by giving an initial oral dose of deuterium-labelled terodiline (12.5 mg or 25 mg) followed by multiple doses of Mictrol tablets (12.5 mg b.i.d. for 14 days and 25 mg b.i.d. for 14 days or vice versa). The enantiomer serum concentration ratio of S(-)/R(+) terodiline was close to unity at steady-state as well as during the disposition phase. The average single-dose kinetic parameters for the racemate after the 12.5 mg dose were: maximum serum concentration 41 micrograms/l, the corresponding time 3.4 hr, terminal half-life 61 hr, oral clearance 77 ml/min., renal clearance 12 ml/min. and apparent volume of distribution 382 1. The single-dose kinetics for the 25 mg dose and the multiple-dose kinetic parameters showed that linear kinetics prevailed. The average steady-state serum concentration was 275 micrograms/l at the lower dose and 509 micrograms/l at the higher dose. The degree of fluctuation during a dosage interval was 19% and the time to steady-state was about 9 days. The fraction unbound was about 8%. Unconjugated p-hydroxylated terodiline, p-hydroxy-m-methoxyterodiline and hydroxy-tert-butyl-terodiline constituted 15%, < 1% and 5%, respectively, of the terodiline steady-state levels.
authors.affiliation: Department of Pharmacokinetics, R & D, Kabi Pharmacia AB, Uppsala, Sweden.
authors.forename: B
authors.initials: B
authors.lastname: Hallén
authors.forename: J
authors.initials: J
authors.lastname: Gabrielsson
authors.forename: S
authors.initials: S
authors.lastname: Nyambati
authors.forename: A
authors.initials: A
authors.lastname: Johansson
authors.forename: E
authors.initials: E
authors.lastname: Larsson
authors.forename: O
authors.initials: O
authors.lastname: Guilbaud
mesh_terms: D000328:Adult; D000368:Aged; D002082:Butylamines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007536:Isomerism; D008297:Male; D008875:Middle Aged
chemical_list: D002082:Butylamines; D002121:Calcium Channel Blockers; C010637:terodiline